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Abstract. This work describes the topological analysis of the vascula-
ture of tumours. The analysis is performed with a scale-space technique,
which traces the centrelines of vessels as topological ridges of the image
intensities and then obtains a series of measurements, which are used to
compare the vasculatures. Besides the measurements directly associated
with the centrelines, the scales obtained allow the estimation of width
and thus area covered with vessels.
Tumours of SW1222 human colorectal carcinoma xenografts were ob-
served when growing in dorsal skin-fold window chambers in mice. Three
variants of the tumours expressing either endogenous levels of angiopoi-
etins (WT) or over-expressing either angiopoietin-1 (Ang-1) or angiopoietin-
2 (Ang-2) were assessed with/without vascular targeted therapy. The
scale-space technique was able to discriminate between the vasculatures
of the three di↵erent tumour types prior to treatment. Results also sug-
gested that over-expression of Ang-2 was associated with susceptibility
of the tumour vasculature to the vascular disrupting agent, combretas-
tatin A4 phosphate (CA4P). Substantiation of this finding would point
to the potential of tumour Ang-2 expression as a predictive bio-marker
for response to CA4P.
Keywords: Scale Space Analysis, Tracing of Vasculature, Vascular Dis-
rupting Agents, CA4P, Tumour Microcirculation, Angiopoietin
1 Introduction
The process of formation of new vessels, in which capillaries sprout from existing
vessels is known as angiogenesis [1] and, in adults, this process is restricted to
relatively few situations such as the female reproductive cycle [2] and patholog-
ical processes such as growth of collaterals in response to obstructive arterial
disease [3, 4], wound healing and tumour growth [5]. In the case of tumours, the
new vasculature has become an attractive therapeutic target to prevent nutrients
and oxygen reaching the tumour as well as preventing metastasis [6, 7].
Angiogenesis is largely driven by a series of growth factors, of which the
angiopoietin family of proteins play a substantial role. The angiopoietins work
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in concert with vascular endothelial growth factor A (VEGFA), with VEGFA
stimulating formation of the initial vascular plexus and angiopoietin-1 (Ang-1)
promoting vascular re-modelling, maturation and stabilisation [8]. During early
phases of vascular sprouting, angiopoietin-2 (Ang-2) can act as a functional
antagonist of Ang-1 that destabilises blood vessels prior to vascular sprouting or
regression, although the precise functions of Ang-2 are highly context dependent
[9].
The microtubule depolymerising agent, combretastatin A4 phosphate (CA4P;
fosbretabulin) is currently in clinical trial (http://www.mateon.com) as a tumour
vascular disrupting agent (VDA) that causes selective tumour blood flow shut-
down, necrosis and growth retardation in solid tumours. Susceptibility of the
tumour vasculature to CA4P is thought to relate to an immature vascular pheno-
type [7]. Therefore, we hypothesised that tumours over-expressing Ang-2 would
be more susceptible to CA4P than those over-expressing Ang-1 or unmodified
tumours, pointing to the potential of tumour angiopoietin expression analysis
for predicting response to CA4P.
Murine dorsal skin-fold window chambers [10] provide a means to observe
developing tumour blood vessels microscopically in longitudinal studies. Quan-
titative assessment of the angiogenesis process can be performed via analysis of
the topological or chromatic characteristics of the resulting optical images [11].
In this work, we assessed the influence of angiopoietin expression in tumours
through the comparison of a series of topological parameters: number of vessels,
length, width and relative area. The mathematical description of the topology
was obtained through a fully automatic vessel tracing algorithm [11] based on
the scale-space ridge detection algorithm proposed by Lindeberg [12, 13].
2 Materials and Methods
2.1 Data sets
SW1222 human colorectal carcinoma cells, kindly supplied by Professor Barbara
Pedley, University College London, UK, were transfected with angiopoietin-1 or
angiopoietin-2 cDNA cloned into pcDNA3.1 mammalian expression vector or
with empty pcDNA-3.1 vector alone. cDNA was kindly supplied by Professor
Pam Jones, University of Leeds, UK. The resulting cells transfected with empty
vector were designated wild-type (WT). Stable transfectants were selected in
G418-containing medium and translation of appropriate gene products was con-
firmed by western blotting (data not shown). Cells over-expressing angiopoietin-1
or angiopoietin-2 were designated Ang-1 and Ang-2 respectively.
Methodological details of the animal experimentation have been described
previously [14], but are included here briefly for completeness. Animal exper-
iments were conducted in accordance with the United Kingdom Home O ce
Animals (Scientific Procedures) Act 1986, with local ethical approval and in
line with the published Guidelines for the Welfare of Animals in Cancer Re-
search [15]. Surgical procedures on severe-combined immune-deficient (SCID)
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mice consisted of implanting an aluminium window chamber (total weight ⇠2
g), designed to hold parallel glass windows 200 µm apart to allow tumour growth,
into a dorsal skin-fold under general anaesthesia. SW1222 human colorectal car-
cinoma cells were grown as hanging drop cultures on the lids of 60 mm plastic
petri dishes inverted over dishes containing 4 ml DMEM containing standard
antibiotics. Hanging drops were established from 1⇥ 105 SW1222 cells in 20 µl
DMEM supplemented with 10% foetal calf serum and 4 mmol/l glutamine plus
standard antibiotics. After 3-4 days of growth, the cell aggregates from the drops
were transplanted directly onto the exposed panniculus muscle within the dorsal
skin-fold window chamber preparations and the chambers closed with a glass
cover-slip. Treatments and image capturing were started approximately 10-12
days after surgery.
Mice were implanted with WT, Ang-1 or Ang-2 tumour cells and, once es-
tablished, were treated with either 30 mg/kg of CA4P or saline as a control,
administered intraperitoneally (i.p.). CA4P was kindly supplied by Professor
GR Pettit, Arizona State University, Tempe, AZ, USA.
The distribution of the mice into treatment groups was: Ang-1/CA4P (n =
5), Ang-1/control (n = 6), Ang-2/CA4P (n = 6), Ang-2/control (n = 6),
WT/CA4P (n = 4), WT/control (n = 2). All tumours were observed longi-
tudinally before (time=0) and up to 24 h (time=2.5, 15, 30, 60, 180, 360, 1440
min) after treatment.
Transmitted light images from a Nikon Eclipse E600FN microscope fitted
with a ⇥2.5 and ⇥10 objective and incorporating illumination from a 12 V/100
W halogen light source were acquired from 29 restrained window chamber-
bearing mice at 2 regions of interest (ROI) at di↵erent locations within the
tumours, as illustrated in Fig. 1. In total, four hundred and sixty four im-
ages were acquired and processed.
The variability of the vasculatures obtained is illustrated in Fig. 2. Control
tumours experienced remodelling of the vasculature within this time period, as
illustrated in Fig. 3.
2.2 Scale Space Analysis
The scale-space approach [12, 13] is a multiscale technique in which a progressive
low pass filtering is applied to an image with the intention of detecting features
of di↵erent dimensions. The features can be of di↵erent nature, e.g. ridges, edges
or blobs. Fine features will be detected at initial scales, with minimal smoothing,
whilst large or coarse features will be detected with considerable smoothing of
the images. Scale-space algorithms are intensity-based as opposed to clustering
or deformable models. The details of the implementation of a scale-space vessel
tracing implementation have been previously described in [11]. Essentially, the
centreline of vessels was detected as a ridge with the intensity f of a given pixel at
position (x, y) as the height in a topographical analogy. It is important to notice
some limitations of the method: (a) the intensity of a physiological vessel in the
image will guide the tracing process. Therefore, if a vessel does not show contrast
against the tissue it may not be traced; (b) a physiological vessel may experience
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(a) (b)
Fig. 1: (a) Illustration of a dorsal skin-fold window chamber, which is implanted
in the dorsal skin of a mouse and through which the vasculature of a tumour
can be observed over time. (b) One representative image acquired with a ⇥2.5
microscope objective. The size of the regions of interest to be captured with a
⇥10 microscope objective is illustrated with white and yellow boxes.
changes of intensity within its centreline and in some cases a single vessel may
appear as two segments or traced vessels; (c) crossings of vessels may imply
discontinuity of the tracing. Thus, the measurement of number of vessels should
be considered as an approximation and may di↵er from a manually obtained
measurement.
The scale-space representation of a function f(x, y) can be defined as the
convolution with a Gaussian g(x, y; t) where t corresponds to the width of a
Gaussian:
L(x, y; t) = g(x, y; t) ⇤ f(x, y) = 1
(2⇡t)
e 
(x2+y2)
(2t) ⇤ f(x, y) (1)
Then, the Hessian Matrix can be formed with the normalised first and second
derivatives in x and y dimensions (Lx,Lxx, Ly, Lyy).
H =

@x@xf @y@xf
@x@yf @y@yf
 
=

Lxx Lyx
Lxy Lyy
 
(2)
Regions of maxima and minima in H were calculated when the derivatives
reached zero. To obtain the centrelines of vessels, or ridges in a topological
analogy, it was necessary to convert from the (x, y) coordinate system to a local
(p, q) system aligned with the eigendirections of H:
Lp = @pL = (sin @x   cos @y)L,
Lq = @qL = (cos @x + sin @y)L,
Lpq = @p@qL = (cos @x + sin @y)(sin @x   cos @y)L, (3)
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(a) Ang-1/CA4P
(d) Ang-1/Control
(b) Ang-2/CA4P
(e) Ang-2/Control
(c) WT/CA4P
(f) WT/Control
Fig. 2: ROIs from tumours within di↵erent treatment groups showing represen-
tative vasculatures. Notice the variability of vasculature in terms of size, density,
colour, etc.
where   denotes the angle of rotation of the coordinate system and it was defined
by:
cos 
    
(x0,y0)
=
r
1
2
⇣
1 + Lxx Lyy
(Lxx Lyy)2+4L2xy
⌘    
(x0,y0)
,
sin 
    
(x0,y0)
= (sign(Lxy))⇥
r
1
2
⇣
1 + Lxx Lyy
(Lxx Lyy)2+4L2xy
⌘    
(x0,y0)
. (4)
The ridges at di↵erent scales constituted a scale-space ridge surface and were
defined as the points of (Lp, Lpp, Lq, Lqq) that fulfilled the conditions of maxima
at every scale. L,Lx, Ly, Lpp, and Lqq are illustrated in Fig. 4 for three scales.
Finally, a scale-space ridge was simplified from the ridge surface by selecting
the points where the surface had maximal values by a given norm. Thus, fine
ridges were detected at fine scales, whilst coarse ridges had higher norm values
at larger scales. A scale-space vessel was subsequently defined as an individual
ridge detected by the algorithm, noticing that the changes of intensity may break
a physical vessel into two or more vessels.
A large number of measurements can be obtained from the traced vessels, but
for this work we concentrated on the following: number of vessels, average vessel
length, average vessel diameter, and relative area of the ROI covered by vessels.
The length and number are direct measurements. The diameter is estimated as
proportional to the scale where the ridge was selected. The area is derived from
the combination of diameter and the length of each traced vessel. The relative
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0 min 2.5 min 15 min 30 min
60 min 180 min 360 min 1440 min
Fig. 3: Longitudinal acquisition of one tumour. Notice the variation of the thick-
ness and position of the vasculature.
area is the ratio of the area previously calculated over the total area of the
tumour tissue in the ROI. In addition, it is possible to rank the vessels by their
saliency, i.e. the contrast between the vessel itself and the surrounding regions,
in order to distinguish the top 5, 10, 50, etc. vessels. Fig. 5 illustrates results of
length, diameter, area and saliency for two time points of the tumour of Fig. 3.
All algorithms were implemented in MATLAB R  (The MathworksTM, Nat-
ick, USA). Statistical tests of one-way Analysis of Variance (ANOVA) followed
by a Tukey post-test to compare individual groups were performed in MATLAB
and GraphPad Prism v7.0b.
3 Results and Discussion
The 464 images described in section 2.1 were traced with the scale-space algo-
rithm previously described. The following measurements were selected for analy-
sis: number of vessels, average diameter, average length and relative area covered
by the vessels. Each of these measurements was calculated for the three di↵erent
tumour types (Ang-1, Ang-2, WT), two ROIs (1, 2), treated or control (CA4P,
control) and eight time points (1 - 8). Data from the two ROIs were pooled for
each tumour.
Results for the three tumour types at time t = 0, that is before treatment
was administered, are shown in Fig. 6. p   values for a one-way ANOVA test
with a Tukey post-test are presented within the figure. Boxplot whiskers indicate
minimum and maximum values, and the box is formed by lines at the median,
first and third quartiles.
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Fig. 4: Illustration of a Scale-Space process where the intensity of an image is fil-
tered at di↵erent scales (vertical) and derivatives in di↵erent directions highlight
features at each scale.
Ang-1 tumours displayed higher average length, diameter and relative area of
blood vessels compared with Ang-2 tumours (Fig. 6). Furthermore, the relative
area measurement was significantly lower for Ang-2 tumours than either Ang-1
tumours or WT tumours. Ang-1 expression has previously been associated with
development of wide vessels, consistent with these findings [9]. Ang-2 can act
as an antagonist for Ang-1, causing vessel destabilisation [16–21], which may
also have contributed to our results. Interestingly, angiopoietin over-expression
did not influence the number of vessels identified by the algorithm (Fig. 6(a)),
suggesting that e↵ects were confined to the diameter and length and not the
number of traced vessels.
Figures 7, 8, 9 and 10 show the e↵ects of CA4P treatment versus control
over time on the four vascular parameters shown in Fig 6, for each of the three
tumour types. The number of vessels remained relatively stable in each of the
tumour types over time, whether treated with CA4P or not. However, CA4P
appeared to reduce average diameter and length of blood vessels in all tumour
types within 3 h of treatment (Figs. 7 and 8), leading to a similar e↵ect on
vascular area (Fig. 10). This confirms the rapid response of tumour vasculature
to CA4P reported in other tumour types (e.g. [22]). In general, Ang-2 tumours
were most a↵ected by CA4P, although further work, including functional assays,
would be needed to determine whether di↵erences in response are statistically
significant.
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(a) 0 min (b) 0 min (c) 24 h (d) 24 h
Fig. 5: (a,c) Traced vessels overlaid on two time points from a single tumour. The
vessels have been ranked and the top 10 are traced in red, 11-50 are traced in
light green and the rest in thinner black lines. Notice the changes of the vascular
topology over time. (b,d) Traced vessels and the inferred thickness of each vessel
denoted by dark shading. The relative area covered was obtained by the ratio of
the shaded pixels over the total area of the image.
4 Conclusions
The scale-space algorithm here described was an e↵ective technique to analyse
the topological variation of the vasculature of three di↵erent tumour types. Be-
sides the vascular parameters analysed here, it would be possible to extract other
parameters such as total length of the vasculature, length of longest vessels and
branching patterns or other non-geometrical measurements such as saturation
or hue.
The results presented here are consistent with Ang-1 acting as a stabilising
influence in angiogenesis and Ang-2 having antagonistic properties. However,
further analysis is required as the e↵ects of Ang-2 have been reported to have
opposing e↵ects under di↵erent circumstances such as in the presence of VEGFA
[17, 23] or in the lymph versus blood vessel networks [24]. The well known tu-
mour vascular disrupting e↵ect of CA4P was confirmed in the current study and
there was a suggestion that tumour cell over-expression of Ang-2 resulted in an
increased response to CA4P. If this is substantiated in further studies, it would
confirm our hypothesis and point to the potential of tumour angiopoietin expres-
sion analysis for aiding the development of predictive biomarkers of response to
CA4P.
5 Code
The code and a brief user manual is freely available as Matlab functions from
the author’s website:
http://www.sta↵.city.ac.uk/ sbbk034/tracingD.php?idMem=software
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Fig. 6: Boxplots summarising the statistical di↵erence between the three tumour
types at time t = 0, before the start of treatment. The p   values for 1-way
ANOVA followed by a Tukey post-test are included within the figures. There
was a statistical di↵erence between Ang-1 and Ang-2 for the diameter, length
and relative areas, and between Ang-2 and WT for relative area only.
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